Alzheimer’s Drug Lecanemab Shields Brain from Free-Roaming Amyloid Fibrils

Amyloid beta protein forms small aggregates that disrupt brain function in Alzheimer’s disease.
Lecanemab, a recently FDA-approved Alzheimer’s treatment, can neutralize these disruptive aggregates, hinting at its potential to slow down the disease’s cognitive decline.

#Neuroscience #Brain #Neurology #NeurologicalDiseases #NeurodegenerativeDiseases #Neurodegeneration #Astrocyte #Neuron #Alzheimer #CognitiveDecline #CognitiveDysfunction #MemoryLoss #BetaAmyloid #AmyloidFibrils #Immunotherapy #Lecanemab

https://neurosciencenews.com/amyloid-fibril-neuropharmacology-23207/